5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)
    Meeting Abstract

    Galsky, M. D.; Grande, E.; Necchi, A.; Koontz, M. Z.; Iyer, G.; Campbell, M. T.; Drakaki, A.; Loriot, Y.; Sokolowski, K. M.; Zhang, W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Apolo, A. B.; Sridhar, S. S.; Chen, R. C.; Wen, Y.; Yen, A. E.; Grivas, P.; Tan, A. L.; Baghaie, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Wang, L.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Mak, B.; Tran, B.; Pashankar, F. D.; Mazhar, D.; Huddart, R. A.; Wheater, M.; Walpole, E. T.; Feldman, D. R.; Dunwoodie, E.; Lawrence, N. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma
    Meeting Abstract

    Aggen, D. H.; Garcia, A.; Saro Suarez, J. M.; Sauer, A.; Cristiani, S.; Brophy, F. E.; Streets, S.; Norry, E.; Nelson, A. A.; Kilari, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma
    Meeting Abstract

    Iyer, G.; Gao, X.; Rasco, D. W.; Milowsky, M. I.; Garmezy, B.; Rivera, I. I. R.; Tepper, J.; Moles, M. A.; Gjini, E.; Bowden, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Iyer, G.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)
    Meeting Abstract

    Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save